Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention
SBIR Award Received From The US NIAID
Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.
You may also be interested in...
Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
GlaxoSmithKline has initiated Phase III studies, EAGLE-1 and EAGLE-2, of potentially a new chemical class of oral antibiotic in patients with infections of public health concern, gonorrhea and urinary tract infections.